These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29260607)

  • 21. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.
    Nishimura K; Saegusa J; Matsuki F; Akashi K; Kageyama G; Morinobu A
    Arthritis Rheumatol; 2015 Apr; 67(4):893-902. PubMed ID: 25545152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.
    Bilori B; Thota S; Clemente MJ; Patel B; Jerez A; Afable Ii M; Maciejewski JP
    Leukemia; 2015 Dec; 29(12):2427-9. PubMed ID: 26449659
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of Alopecia Areata With Tofacitinib.
    Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
    JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
    Gregory MH; Ciorba MA; Deepak P; Christophi GP
    Inflamm Bowel Dis; 2019 Jun; 25(7):e87-e88. PubMed ID: 30753456
    [No Abstract]   [Full Text] [Related]  

  • 27. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
    Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Furuya M; Gunji N; Fujiwara T; Asano T; Onizawa M; Kobayashi H; Watanabe H; Ohira H; Migita K
    Rheumatology (Oxford); 2020 Jul; 59(7):1773-1775. PubMed ID: 31776552
    [No Abstract]   [Full Text] [Related]  

  • 28. [Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].
    Harada T; Nakamura H
    Nihon Yakurigaku Zasshi; 2014 Sep; 144(3):133-41. PubMed ID: 25213614
    [No Abstract]   [Full Text] [Related]  

  • 29. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
    Liu S; Li C; Tang MW; Xu WS; Chen KQ; Sui X; Tian XL; Xu KF
    Chin Med J (Engl); 2019 Oct; 132(19):2378-2379. PubMed ID: 31503058
    [No Abstract]   [Full Text] [Related]  

  • 31. Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
    Noell C; Arbeit R; Kanhoush R
    Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lung Disease: A Rare but Devastating Complication of Systemic Juvenile Idiopathic Arthritis and the Use of Tofacitinib as a Treatment.
    Kaplan MM; Cinel G; Çelikel E
    Arch Bronconeumol; 2024 Jun; 60(6):374-375. PubMed ID: 38402050
    [No Abstract]   [Full Text] [Related]  

  • 33. Malignancy and Janus Kinase Inhibition.
    Sivaraman P; Cohen SB
    Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
    Curtis JR; Lee EB; Martin G; Mariette X; Terry KK; Chen Y; Geier J; Andrews J; Kaur M; Fan H; Nduaka CI
    Clin Exp Rheumatol; 2017; 35(4):614-622. PubMed ID: 28240592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
    Gök K; Cengiz G; Erol K; Ozgocmen S
    Acta Reumatol Port; 2017; 42(1):88-90. PubMed ID: 28371574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
    Winthrop KL; Silverfield J; Racewicz A; Neal J; Lee EB; Hrycaj P; Gomez-Reino J; Soma K; Mebus C; Wilkinson B; Hodge J; Fan H; Wang T; Bingham CO
    Ann Rheum Dis; 2016 Apr; 75(4):687-95. PubMed ID: 25795907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
    Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
    Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.